Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

PHASE2CompletedINTERVENTIONAL
Enrollment

265

Participants

Timeline

Start Date

November 7, 2015

Primary Completion Date

May 5, 2016

Study Completion Date

April 28, 2017

Conditions
Seasonal Allergic Rhinitis
Interventions
BIOLOGICAL

Placebo (0.5ml)

BIOLOGICAL

Placebo (1.0ml)

BIOLOGICAL

Grass MATA MPL (0.5ml) 5100SU

BIOLOGICAL

Grass MATA MPL (1.0ml) 10200SU

BIOLOGICAL

Grass MATA MPL (1.0ml) 18200SU

BIOLOGICAL

Grass MATA (0.5ml) 5100SU

Trial Locations (1)

07753

Inflamax Research Inc., Neptune City

Sponsors
All Listed Sponsors
lead

Allergy Therapeutics

INDUSTRY